Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer

7Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVES: The aim of this study was to investigate the prognostic factors for post-recurrence survival (PRS) in patients with completely resected Stage III (N2) non-small-cell lung cancer. METHODS: A number of clinicopathological factors were evaluated to identify the prognostic factors for recurrence-free survival using Cox proportional hazards models in 245 patients who underwent complete resection of pathological Stage III (N2) non-small-cell lung cancer. Additional post-recurrence data were evaluated, including the presence of symptoms of recurrence, the recurrence pattern, the treatment modality and the recurrence-free interval (RFI). The prognostic effects of clinicopathological factors before recurrence and the additional post-recurrence data on PRS were analysed. RESULTS: A total of 124 patients experienced recurrence during a median follow-up period of 39.8 months. Twenty-one patients were symptomatic at the time of initial recurrence, and the mean RFI was 14.0 months. Loco-regional recurrence was observed in 38 (31%) patients, distant metastasis in 33 (27%) patients and both in 53 (42%) patients. The initial treatment modality was surgery in 17 (14%) patients, chemotherapy in 66 (53%) patients, radiotherapy in 17 (14%) patients and chemoradiotherapy in 18 (15%) patients. The median duration of PRS was 30.5 months (range 1 109 months), and the 1-, 3-and 5-year PRS rates were 72%, 43% and 23%, respectively. A shorter RFI and radiotherapy for the treatment of recurrence were found to be independent prognostic factors for PRS in the multivariable analysis. CONCLUSIONS: The prognostic factors for recurrence-free survival were not associated with PRS, and a shorter RFI and radiotherapy for the treatment of recurrence were found to be negative prognostic factors for PRS.

References Powered by Scopus

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7638Citations
N/AReaders
Get full text

Erlotinib in previously treated non-small-cell lung cancer

5253Citations
N/AReaders
Get full text

Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship

3219Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pattern of recurrence of pN2 non-small-cell lung cancer: Should postoperative radiotherapy be reconsidered?

13Citations
N/AReaders
Get full text

Clinicopathological factors related to recurrence patterns of resected non-small cell lung cancer

13Citations
N/AReaders
Get full text

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cho, S., Yum, S., Kim, K., & Jheon, S. (2018). Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery, 54(3), 554–559. https://doi.org/10.1093/ejcts/ezy063

Readers over time

‘15‘18‘19‘20‘21‘2200.751.52.253

Readers' Seniority

Tooltip

Professor / Associate Prof. 3

38%

PhD / Post grad / Masters / Doc 3

38%

Researcher 2

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

100%

Save time finding and organizing research with Mendeley

Sign up for free
0